[./indexpag.html]
[./company_overviewpag.html]
[./teampag.html]
[./newspag.html]
[./employmentpag.html]
[./technologypag.html]
[./research_servicespag.html]
[./contact_uspag.html]
Technology Overview: DIRECT SELECTION OF HYBRIDOMAS (DiSH)
Monoclonal antibodies are now at the center of drug and diagnostic product development in the biotech/pharmaceutical industry. In certain cases, multiple companies are developing monoclonal antibodies raised against the same targets and for the same medical indications. As a result, the winning products are likely to be those with the best combination of development speed and optimal characteristics (e.g., affinity, specificity, functionality and immunoglobulin sub-type). The challenge of screening and production First developed in 1975, conventional hybridoma technology is not designed for high-volume generation of monoclonals. The primary bottleneck for high-volume hybridoma production occurs in the limiting dilution screening (LDS) stage of the process. During this step, the relatively few hybridoma cells (typically 1 to 200) that are producing antibodies of interest must be manually identified and isolated from among a very large heterogeneous population of cells (typically 10 to 100 million). This screening and isolation process is labor intensive, requiring upwards of 90 days to complete. More problematic, hybridomas producing valuable antibodies are routinely lost using current methods. Cells of interest are frequently unstable or slow growing, and hence, are overgrown by uninteresting cells before the cloning process is complete. Direct Selection of Hybridomas (DiSH) Abeome's DiSH technology, offers a much-improved method for selecting desired hybridomas that produce valuable antibodies. Genetic engineering techniques were used to modify the myeloma partner which, when fused to the antibody-producing lymphocyte, causes the resulting hybridoma to present significantly greater surface antibody. The cells of interest can then be identified using fluorescent-labeled antigen, and deposited into single cell microtiter wells using commercially-available technology fluorescence-activated cell sorting (FACS). The net result is that DiSH technology dramatically accelerates hybridoma production, greatly increasing the yield of hybridomas producing monoclonals with high-affinity to antigen targets that would otherwise be lost using conventional methods.
Copyright © 2006 Abeome Corp. All rights reserved.
[#ANCHOR_Img1]
Return to top
Benefits of DiSH Technology
Significant Reductions in Cycle Time High speed sorting using FACS enables a reduction in the amount of time to sort from 3+ months to 22 to 28 days. Dramatic Improvement in Target Yield Using FACS to deposit target hybridomas in single wells avoids the loss of high quality hybridomas due to overgrowth from competing cells, leading to significantly higher yield and high-affinity of desired hybridomas from each screening initiative.
[./partneringpag.html]
[./indexpag.html]
HOME
[Web Creator] [LMSOFT]